Find The Best Stocks to Buy Today

This biotech giant could capture a bigger chunk of a $150B market.‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

"NVO just handed LLY a major win – and I think the market hasn't fully priced it in yet." Bryan Bottarelli, Co-Founder, Monument Traders Alliance Nvidia. Google. Microsoft. The AI trade minted fortunes over the last three years. But in 2026, I believe that trade is finally running out of road… for everyone except the most fundamentally sound companies involved in AI. The reason is simple: AI is getting expensive. The infrastructure bill is coming due. With data centers alone projected to require $6.7 trillion in compute spending by 2030. When one sector like AI gets too pricey, money looks for a new place to go. And with AI accelerating drug discovery and clinical data analysis, I believe the biotech/healthcare sector is the logical place for money to land next. (My Monument Trend Advisory subscribers know this... we focused on the sector in our February issue, along with three biotech recommendations.) One biotech group I'm watching right now is Eli Lilly (LLY). Here's why I like LLY for a potential trade…. Yesterday morning, shares of rival biotech group Novo Nordisk (NVO) were down 15% after the company's latest weight loss drug, CagriSema, failed to match Eli Lilly's tirzepatide in a head-to-head trial. Obesity and metabolic drugs are already a $100-150 billion annual market – and it's still in the early innings. What's bad news for NVO is fantastic news for LLY - as this solidifies their GLP-1 drug as the best in class - and further establishes their leadership position for new patients. Overall, LLY could become one of the largest cash flow machines in healthcare. SPONSORED Missed Tesla? PayPal? SpaceX? You Might Regret Missing This One Too… Many are calling him The Next Elon Musk… His first company made investors 6,566% before the age of 25… Now, he’s building one of the most-anticipated companies in the world… with $26 billion in government contracts already in place. And one rare 4-letter ticker gives you early access — before the IPO. Click here now to watch the briefing. Action Plan: I believe LLY could be in for a short-term spike with rival NVO coming up short in its latest drug trial. It's on my watchlist for a trade right now in The War Room. My colleague Karim also recently revealed a fundamentally sound company that could completely revolutionize AI – and few people have heard of it. Click here to unlock this play today. SPONSORED Alexander Green Reveals The Top Trump Trades for 2025 Wharton's Jeremy Siegel says Trump is "the most pro-stock market president we've had in our history." And the numbers back it up. During Trump's first term, innovative companies soared: TradeDesk jumped 2,500% Digital Turbine soared 8,000% Enphase Energy returned 9,700% Now, with Trump's new economic blueprint in place, investment expert Alexander Green has identified a handful companies set to lead the next wave of wealth creation... And Alex is revealing their names and ticker symbols, free of charge. → CLICK HERE TO WATCH NOW Monument Traders Alliance, LLC   You are receiving this email because you subscribed to Trade of the Day Wake-Up Watchlist. To unsubscribe from Trade of the Day Wake-Up Watchlist, click here. Questions? Check out our FAQs. Trying to reach us? Contact us here. Please do not reply to this email as it goes to an unmonitored inbox. To cancel by mail or for any other subscription issues, write us at: Trade of the Day | 14 West Mount Vernon Place | Baltimore, MD 21201 North America: 800.507.1399 | International: +1.443.353.4977 Website | Privacy Policy Keep the emails you value from falling into your spam folder. Whitelist Trade of the Day. © 2026 Monument Traders Alliance, LLC | All Rights Reserved       Nothing published by Monument Traders Alliance should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed personalized investment advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after publication before trading on a recommendation. Any investments recommended by Monument Traders Alliance should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. The information found on this website may only be used pursuant to the membership or subscription agreement and any reproduction, copying or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of Monument Traders Alliance, LLC, 14 West Mount Vernon Place, Baltimore, MD 21201. REF: 000122325764